Alpelisib Patent Expiration

Alpelisib was first introduced by Novartis Pharmaceuticals Corp in its drug Piqray on May 24, 2019. Another drug containing Alpelisib is Vijoice.

Alpelisib Patents

Given below is the list of patents protecting Alpelisib, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in	Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Drug Owner
Piqray	US8227462	Pyrrolidine-1,2-dicarboxamide derivatives	Apr 29, 2033	Novartis
Vijoice	US8227462	Pyrrolidine-1,2-dicarboxamide derivatives	Apr 29, 2033	Novartis
Piqray	US8476268	Pyrrolidine-1,2-dicarboxamide derivatives	Sep 10, 2029	Novartis
Vijoice	US8476268	Pyrrolidine-1,2-dicarboxamide derivatives	Sep 10, 2029	Novartis

Drugs Generating Over $1 Billion in Annual Revenue

Explore the top-performing drugs that dominate the pharmaceutical industry

View List

NCE-1 Patent Expiry in the Next 1 Year

Identify opportunities as new chemical entity (NCE-1) patents approach expiry

View List

Recently Granted Patents in EP

Find the opportunity to file Oppositions

View List